MEDICATION, is critical in maintaining health as it is used to diagnose, cure, treat, or prevent disease, though it is currently inhibited by threatening increase of Anti-Microbial Resistance (AMR).
It
is evident that AMR, which is the development of resistance in a microorganism such
as bacteria, virus, fungus or parasite or to an antimicrobial agent to which it
was previously sensitive requires urgent attention in Zambia.
Antimicrobial treatment is a major lifesaving intervention for infectious diseases. These can also be extensively used in animal health, agriculture and the environment sectors.
One of the biggest contributors of AMR in the country and world over is the increasing and lack of effective controls in the use of antibiotics in the human health system, veterinary medicine, agriculture, horticulture and aquaculture.
Government of Zambia working with partners is in support a robust plan to address AMR said to be an increasingly serious threat to global public health that requires action across all government sectors and society.
Recently,
a multidisciplinary team met in Lusaka to chat the way forward in addressing
AMR with representation from various sectors and institutions with the aim of
developing an implementation plan for Zambia’s Multi-sectoral National Action
plan on Antimicrobial Resistance.
This was in an effort to devise new approaches towards infectious diseases affecting human, animal and plant health through attention on Anti-Microbial Resistance.
Ministry of Health Permanent Secretary in charge of Technical Services Kennedy Malama guided through Public Health Director Dr Andrew Silumesii that there was need to adequately develop policies on the use of AMRs and one of the key strategies for reducing the emergence and spread of this resistance was optimizing the use of antimicrobials in human, animal, and plant health.
This was in an effort to devise new approaches towards infectious diseases affecting human, animal and plant health through attention on Anti-Microbial Resistance.
Ministry of Health Permanent Secretary in charge of Technical Services Kennedy Malama guided through Public Health Director Dr Andrew Silumesii that there was need to adequately develop policies on the use of AMRs and one of the key strategies for reducing the emergence and spread of this resistance was optimizing the use of antimicrobials in human, animal, and plant health.
“Although intended for therapeutic use only in animals, antimicrobials, antibiotics in particular, are globally used for non-therapeutic purposes such as for growth promotion and mass disease prevention" said Dr Malama
He
said Global guidance have emphasized the need for adequate policies to limit
such non-therapeutic antibiotic use hence the need to adequately tackle the
subject.
Ministry of Health is working closely with Ministry of Fisheries and Livestock, researchers and scientists from various institutions to put to halt this threat.
Fisheries and Livestock Permanent Secretary David Shamulenge represented by Deputy Director of Veterinary Medicine Dr. Francis Mulenga to the team to prioritise investment into AMR research to help formulate informed policies.
Ministry of Health is working closely with Ministry of Fisheries and Livestock, researchers and scientists from various institutions to put to halt this threat.
Fisheries and Livestock Permanent Secretary David Shamulenge represented by Deputy Director of Veterinary Medicine Dr. Francis Mulenga to the team to prioritise investment into AMR research to help formulate informed policies.
In 2018, Zambia launched its first 10-year multi-sectoral antimicrobial resistance (AMR) National Action Plan following a One Health approach.
This was arrived at after a wide consultative process with line ministries and cooperating partners. The plan aims to implement interventions across the key One Health sectors to fight AMR strategically and collaboratively.
The plan tagged at $17 million investment prioritised awareness and education, surveillance and research, infection prevention, sanitation and hygiene, optimising drug use and funding for research and development. ***